[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 13 of about 13
1. Marini F, Falchetti A, Del Monte F, Carbonell Sala S, Gozzini A, Luzi E, Brandi ML: Multiple endocrine neoplasia type 1. Orphanet J Rare Dis; 2006;1:38
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple endocrine neoplasia type 1.
  • Multiple Endocrine Neoplasia type 1 (MEN1) is a rare autosomal dominant hereditary cancer syndrome presented mostly by tumours of the parathyroids, endocrine pancreas and anterior pituitary, and characterised by a very high penetrance and an equal sex distribution.
  • It occurs in approximately one in 30,000 individuals.
  • The sporadic form presents with two of the three principal MEN1-related endocrine tumours (parathyroid adenomas, entero-pancreatic tumours and pituitary tumours) within a single patient, while the familial form consists of a MEN1 case with at least one first degree relative showing one of the endocrine characterising tumours.
  • Other endocrine and non-endocrine lesions, such as adrenal cortical tumours, carcinoids of the bronchi, gastrointestinal tract and thymus, lipomas, angiofibromas, collagenomas have been described.
  • The responsible gene, MEN1, maps on chromosome 11q13 and encodes a 610 aminoacid nuclear protein, menin, with no sequence homology to other known human proteins.
  • MEN1 syndrome is caused by inactivating mutations of the MEN1 tumour suppressor gene.
  • The combination of clinical and genetic investigations, together with the improving of molecular genetics knowledge of the syndrome, helps in the clinical management of patients.
  • Treatment consists of surgery and/or drug therapy, often in association with radiotherapy or chemotherapy.
  • Currently, DNA testing allows the early identification of germline mutations in asymptomatic gene carriers, to whom routine surveillance (regular biochemical and/or radiological screenings to detect the development of MEN1-associated tumours and lesions) is recommended.
  • [MeSH-major] Multiple Endocrine Neoplasia Type 1 / diagnosis. Multiple Endocrine Neoplasia Type 1 / therapy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy. Parathyroid Neoplasms / diagnosis. Parathyroid Neoplasms / therapy. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adrenal Cortex Neoplasms / diagnosis. Adult. Aged. Aged, 80 and over. Angiofibroma / diagnosis. Carcinoid Tumor / diagnosis. Child. Facial Neoplasms / diagnosis. Female. Gastrinoma / diagnosis. Genetic Testing / methods. Humans. Insulinoma / diagnosis. Lipoma / diagnosis. Male. Meningioma / diagnosis. Middle Aged. Prolactinoma / diagnosis. Proto-Oncogene Proteins / genetics. Thyroid Neoplasms / diagnosis. Vasoactive Intestinal Peptide / blood. Vasoactive Intestinal Peptide / secretion. Young Adult

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • Genetic Alliance. consumer health - Multiple endocrine neoplasia type 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Oct 21;18(43):5936-42 [10557080.001]
  • [Cites] Cell. 1999 Jan 8;96(1):143-52 [9989505.001]
  • [Cites] Eur J Endocrinol. 2000 Feb;142(2):131-7 [10664520.001]
  • [Cites] Endocr Relat Cancer. 1999 Dec;6(4):449-73 [10730900.001]
  • [Cites] Mamm Genome. 2000 Jun;11(6):448-54 [10818209.001]
  • [Cites] Mol Cell Endocrinol. 2000 Oct 25;168(1-2):135-40 [11064160.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Aug 17;286(2):426-31 [11500056.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):4917-25 [11526476.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):495-505; discussion 505-6 [11573043.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38197-204 [12145286.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:189-98 [15153434.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Aug;89(8):3776-84 [15292304.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Aug;89(8):4124-9 [15292357.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Oct 22;264(2):404-8 [10529376.001]
  • [Cites] Gastroenterology. 1967 Apr;52(4):695-708 [4290095.001]
  • [Cites] N Engl J Med. 1987 Nov 5;317(19):1200-9 [3309661.001]
  • [Cites] Nature. 1988 Mar 3;332(6159):85-7 [2894610.001]
  • [Cites] N Engl J Med. 1989 Jul 27;321(4):213-8 [2568586.001]
  • [Cites] N Engl J Med. 1989 Jul 27;321(4):218-24 [2568587.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Mar;87(5):1968-72 [1968641.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Mar;52(1):85-92 [1672620.001]
  • [Cites] N Engl J Med. 1992 Jun 25;326(26):1721-6 [1317506.001]
  • [Cites] Endocr Rev. 1992 May;13(2):220-40 [1352243.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jul;75(1):76-81 [1352309.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Oct 1;63(1):17-21 [1358429.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):10914-21 [7902574.001]
  • [Cites] Am J Med. 1994 Nov;97(5):436-44 [7977432.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Feb;79(2):123-6 [7889502.001]
  • [Cites] Arch Surg. 1996 Jul;131(7):699-702 [8678766.001]
  • [Cites] QJM. 1996 Sep;89(9):653-69 [8917740.001]
  • [Cites] Gut. 1996 Oct;39(4):562-8 [8944566.001]
  • [Cites] Medicine (Baltimore). 1997 Jan;76(1):21-9 [9064485.001]
  • [Cites] Science. 1997 Apr 18;276(5311):404-7 [9103196.001]
  • [Cites] Hum Mol Genet. 1997 Jul;6(7):1169-75 [9215689.001]
  • [Cites] Hum Mol Genet. 1997 Jul;6(7):1177-83 [9215690.001]
  • [Cites] Arch Dermatol. 1997 Jul;133(7):853-7 [9236523.001]
  • [Cites] Gastroenterology. 1997 Sep;113(3):773-81 [9287968.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Oct;82(10):3487-92 [9329390.001]
  • [Cites] Hum Mol Genet. 1997 Dec;6(13):2285-90 [9361035.001]
  • [Cites] Eur J Endocrinol. 1997 Dec;137(6):684-7 [9437237.001]
  • [Cites] Jpn J Cancer Res. 1997 Nov;88(11):1029-32 [9439676.001]
  • [Cites] Am J Hum Genet. 1998 Feb;62(2):232-44 [9463336.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1630-4 [9465067.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Mar;109(2):138-40 [10087948.001]
  • [Cites] Mamm Genome. 1999 Jun;10(6):592-6 [10341092.001]
  • [Cites] Biochim Biophys Acta. 1999 Oct 6;1447(1):51-6 [10500243.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Oct;84(10):3775-80 [10523029.001]
  • [Cites] Biochim Biophys Acta. 1999 Sep 3;1446(3):286-94 [10524203.001]
  • [Cites] J Surg Oncol. 2005 Mar 1;89(3):143-50 [15719382.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):367-75 [15864278.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):2603-9 [15713725.001]
  • [Cites] J Invest Dermatol. 1998 Apr;110(4):438-40 [9540988.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jun;22(2):130-7 [9598800.001]
  • [Cites] Lancet. 1997 Oct 25;350(9086):1223 [9652567.001]
  • [Cites] J Intern Med. 1998 Jun;243(6):501-4 [9681849.001]
  • [Cites] Am J Hum Genet. 1998 Aug;63(2):455-67 [9683585.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2685-9 [9703929.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2621-6 [9709921.001]
  • [Cites] N Engl J Med. 1998 Oct 8;339(15):1063-72 [9761809.001]
  • [Cites] J Med Genet. 1998 Nov;35(11):915-9 [9832038.001]
  • [Cites] Surgery. 1998 Dec;124(6):1106-13; discussion 1113-4 [9854591.001]
  • [Cites] Hum Mutat. 1999;13(1):54-60 [9888389.001]
  • [Cites] Eur J Endocrinol. 1999 Nov;141(5):475-80 [10576763.001]
  • (PMID = 17014705.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MEN1 protein, human; 0 / Proto-Oncogene Proteins; 37221-79-7 / Vasoactive Intestinal Peptide
  • [Number-of-references] 64
  • [Other-IDs] NLM/ PMC1594566
  • [General-notes] NLM/ Original DateCompleted: 20070618
  •  go-up   go-down


2. Olubunmi OA: Misdiagnosis of tuberous sclerosis in a Nigerian girl: a case report and review of literature. Ann Afr Med; 2010 Apr-Jun;9(2):95-101
Hazardous Substances Data Bank. VALPROIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Misdiagnosis of tuberous sclerosis in a Nigerian girl: a case report and review of literature.
  • Tuberous sclerosis is a rare neuro-cutaneous syndrome, one of the phakomatosis, characterized by facial angiofibromas (adenoma sebaceum), mental retardation and epilepsy.
  • This classic triad occurs in less than one half of patients, probably in one-third, thus requiring a high index of suspicion to diagnose.
  • This is a case report of tuberous sclerosis in a 13-year-old Nigerian girl that was misdiagnosed as neurofibromatosis because of her cutaneous lesions.
  • This paper discussed the case and reviewed the literature.
  • [MeSH-minor] Adolescent. Angiofibroma / diagnosis. Anticonvulsants / therapeutic use. Diagnostic Errors. Epilepsy / drug therapy. Epilepsy / etiology. Female. Humans. Intellectual Disability / etiology. Neurofibromatoses / diagnosis. Skin Neoplasms / diagnosis. Tomography, X-Ray Computed. Treatment Outcome. Valproic Acid / therapeutic use

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20587932.001).
  • [ISSN] 0975-5764
  • [Journal-full-title] Annals of African medicine
  • [ISO-abbreviation] Ann Afr Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Anticonvulsants; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


3. Rauktys A, Lee N, Lee L, Dabora SL: Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatol; 2008;8:1
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.
  • The molecular mechanism underlying TSC is understood and there is evidence that systemic treatment with rapamycin or other mTOR inhibitors may be a useful approach to targeted therapy for the kidney and brain manifestations.
  • Topical treatments were compared with injected rapamycin and topical vehicle.
  • Rapamycin levels in blood and tumors were measured to assess systemic drug levels in all cohorts.
  • RESULTS: Treatment with topical rapamycin improved survival and reduced tumor growth.
  • Topical rapamycin treatment resulted in systemic drug levels within the known therapeutic range and was not as effective as injected rapamycin.
  • CONCLUSION: Topical rapamycin inhibits TSC-related tumor growth.
  • These findings could lead to a novel treatment approach for facial angiofibromas and other TSC skin lesions.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Enzyme Inhibitors / administration & dosage. Protein Kinases / drug effects. Sirolimus / administration & dosage. Soft Tissue Neoplasms / drug therapy. Tuberous Sclerosis / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Animals. Cell Line, Tumor. Disease Models, Animal. Mice. Mice, Nude. Neoplasm Transplantation. Skin Absorption. Survival Analysis. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] Genet Med. 2007 Feb;9(2):88-100 [17304050.001]
  • [Cites] Am J Hum Genet. 1999 Dec;65(6):1790-5 [10577937.001]
  • [Cites] Hum Genet. 2000 Aug;107(2):97-114 [11030407.001]
  • [Cites] Am J Hum Genet. 2001 Jan;68(1):64-80 [11112665.001]
  • [Cites] Cell. 2001 May 4;105(3):357-68 [11348592.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Aug 15;164(4):661-8 [11520734.001]
  • [Cites] Nat Biotechnol. 2001 Oct;19(10):940-5 [11581659.001]
  • [Cites] J Am Acad Dermatol. 2001 Nov;45(5):731-5 [11606924.001]
  • [Cites] J Cutan Pathol. 2002 May;29(5):287-90 [12100629.001]
  • [Cites] Br J Dermatol. 2002 Aug;147(2):337-42 [12174108.001]
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):699-704 [12172555.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5645-50 [12384518.001]
  • [Cites] J Cutan Pathol. 2003 Mar;30(3):174-7 [12641776.001]
  • [Cites] Lancet. 2003 Apr 19;361(9366):1348-9 [12711473.001]
  • [Cites] Transplantation. 2004 Mar 15;77(5):760-2 [15021843.001]
  • [Cites] Transplantation. 2004 May 15;77(9):1319-26 [15167584.001]
  • [Cites] Clin Transplant. 2004 Aug;18(4):446-9 [15233824.001]
  • [Cites] J Am Acad Dermatol. 2004 Jul;51(1 Suppl):S9-11 [15243489.001]
  • [Cites] J Am Acad Dermatol. 2004 Jul;51(1 Suppl):S11-2 [15243490.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1305-15 [8269512.001]
  • [Cites] Am J Hum Genet. 1996 Aug;59(2):400-6 [8755927.001]
  • [Cites] Science. 1997 Aug 8;277(5327):805-8 [9242607.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1639-47 [9403714.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):19-24 [15624019.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Dec;63(12):1236-42 [15624760.001]
  • [Cites] Pediatr Res. 2005 Jan;57(1):67-75 [15557109.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Mar;42(3):213-27 [15578690.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):69-76 [15661536.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]
  • [Cites] Br J Dermatol. 2005 Apr;152(4):758-64 [15840110.001]
  • [Cites] Eur J Hum Genet. 2005 Jun;13(6):731-41 [15798777.001]
  • [Cites] Br J Dermatol. 2005 Jul;153(1):136-44 [16029339.001]
  • [Cites] J Am Soc Nephrol. 2006 Feb;17(2):581-9 [16434506.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]
  • [Cites] Anticancer Drugs. 2006 Jun;17(5):487-94 [16702804.001]
  • [Cites] Am J Kidney Dis. 2006 Sep;48(3):e27-9 [16931204.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Oct;45(10):933-44 [16845661.001]
  • [Cites] N Engl J Med. 2006 Sep 28;355(13):1345-56 [17005952.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2):189-202 [17637444.001]
  • (PMID = 18226258.001).
  • [ISSN] 1471-5945
  • [Journal-full-title] BMC dermatology
  • [ISO-abbreviation] BMC Dermatol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK066366
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Enzyme Inhibitors; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC2266897
  •  go-up   go-down


Advertisement
4. Belcadhi M, Mani R, Harzallah M, Bouaouina N, Bouzouita K: [Nasopharyngeal angiofibroma with intracranial extension: situating the chemotherapy-radiotherapy association]. Cancer Radiother; 2008 Sep;12(5):385-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nasopharyngeal angiofibroma with intracranial extension: situating the chemotherapy-radiotherapy association].
  • [Transliterated title] L'angiofibrome nasopharyngien avec extension intracrânienne : place de l'association chimiothérapie-radiothérapie.
  • Nasopharyngeal angiofibroma is a locally aggressive, although histologically benign, vascular neoplasm.
  • This neoplasm accounts for 0.05% of head and neck tumours and affects almost exclusively male adolescents.
  • Surgery is considered as the primary treatment of nasopharyngeal angiofibroma.
  • Other treatment modalities such as radiotherapy and chemotherapy are still recommended for intracranial extension involving the cavernous sinus or the internal carotid artery.
  • We report a rare case of nasopharyngeal angiofibroma, further complicated with a Kennedy syndrome in a 34 year-old women.
  • The treatment consisted in a chemotherapy (adriamycine, decarbazine) followed by radiotherapy.
  • We discuss the relevance and outcome of the association chemotherapy-radiotherapy in the treatment of nasopharyngeal angiofibromas with a consistent intracranial extension (stage III B of Arch Otolaryngol Head Neck Surg 122 (2003) 122-129).
  • [MeSH-major] Angiofibroma / drug therapy. Angiofibroma / radiotherapy. Brain Neoplasms / radiotherapy. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18339570.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Durko M, Murlewska A, Gryczyński M, Ratyńska M, Pietruszewska W: [Angiofibroma of the nasal cavity and anterior ethmoid cells--problems in differential diagnosis]. Otolaryngol Pol; 2007;61(5):736-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiofibroma of the nasal cavity and anterior ethmoid cells--problems in differential diagnosis].
  • [Transliterated title] Angiofibroma jamy nosa i komórek sitowych przednich u kobiety--problemy diagnostyki róznicowej.
  • BACKGROUND: Nasal angiofibromas are commonly called juvenile nasal angiofibromas (JNA) because of the almost exclusive occurrence in adolescent males.
  • It is a relatively rare benign fibrovascular tumor originating in the posterior lateral wall of the nasopharynx with only a very few cases diagnosed in females.
  • CASE REPORT: Authors present a case of a 26 y.o. woman with JNA in left nasal cavity with extension to the anterior left ethmoid cells diagnosed and surgically treated at the ENT Department, Medical University of Lodz.
  • Patient presented in past medical history: lymphoma malignum--abdominal location--surgical treatment and chemotherapy (1986) with no clinical signs of recurrence.
  • CT of paranasal sinuses in frontal and axial plains--left nasal cavity filled with a solid pathologic tissue.
  • In the left anterior ethmoid cells extension of the tumor could be seen.
  • Surgical treatment--tumor has been surgically resected with no complications.
  • In a 12 month follow up patient shows no signs of recurrence.
  • CONCLUSION: Although angiofibroma in females is an extremely rare tumor of a sinonasal tract it should be taken into consideration in the differential diagnosis of all nasal cavity tumors (especially solitary fibrous tumor).
  • It is not possible to make differential diagnosis on physical examination.
  • [MeSH-major] Angiofibroma / pathology. Ethmoid Sinus / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Nasal Cavity / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18552009.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


6. Grieb S, Kruse R, Bruch-Gerharz D, Reifenberger J: [Tuberous sclerosis: diagnostic criteria and new treatment approaches]. Hautarzt; 2008 Oct;59(10):774-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tuberous sclerosis: diagnostic criteria and new treatment approaches].
  • With a prevalence of 1 in 6,000 births, tuberous sclerosis is a relatively frequent hamartoma and tumor syndrome inherited as an autosomal dominant trait, which manifests primarily on the skin and in the central nervous system.
  • Treatment for many years consisted solely in using nonspecific symptomatic approaches; dermatological therapy comprised mainly laser or electroacoustic ablation of facial angiofibromas.
  • New models of therapy hinder the pathogenesis of tuberous sclerosis.
  • Synergistic effects were observed in combination therapy with the cytokine IFN-gamma.
  • [MeSH-major] Dermatologic Agents / therapeutic use. Interferon-gamma / therapeutic use. Skin Diseases / diagnosis. Skin Diseases / drug therapy. Tuberous Sclerosis / diagnosis. Tuberous Sclerosis / drug therapy
  • [MeSH-minor] Adult. Humans. Male. Recombinant Proteins

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 1999 May;64(5):1305-15 [10205261.001]
  • [Cites] Pediatr Radiol. 2008 Sep;38(9):936-52 [18414839.001]
  • [Cites] Am J Kidney Dis. 2006 Sep;48(3):e27-9 [16931204.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]
  • [Cites] J Child Neurol. 1998 Dec;13(12 ):624-8 [9881533.001]
  • [Cites] Ann Hum Genet. 2003 Jan;67(Pt 1):87-96 [12556239.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2):189-202 [17637444.001]
  • (PMID = 18806968.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Recombinant Proteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


7. Hofbauer GF, Marcollo-Pini A, Corsenca A, Kistler AD, French LE, Wüthrich RP, Serra AL: The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol; 2008 Aug;159(2):473-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
  • Tuberous sclerosis complex (TSC) is an autosomal dominant disorder with an incidence of approximately one in 6000.
  • It arises from a genetic abnormality involving either the TSC1 gene on chromosome 9 or the TSC2 gene on chromosome 16.
  • Angiofibroma affects 70-80% of patients with TSC, typically on the face.
  • Immunosuppressive treatment with rapamycin, a specific mTOR inhibitor, initiated because of renal transplantation, reduced facial angiofibroma dramatically.
  • [MeSH-major] Angiofibroma / drug therapy. Facial Neoplasms / drug therapy. Sirolimus / therapeutic use. Skin Neoplasms / drug therapy. Tuberous Sclerosis / complications
  • [MeSH-minor] Adolescent. Antibiotics, Antineoplastic / therapeutic use. Female. Humans. Protein Kinase Inhibitors / therapeutic use. Protein Kinases / physiology. TOR Serine-Threonine Kinases


8. Krstulja M, Car A, Bonifacić D, Braut T, Kujundzić M: Nasopharyngeal angiofibroma with intracellular accumulation of SPARC - a hypothesis (SPARC in nasopharyngeal angiofibroma). Med Hypotheses; 2008;70(3):600-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal angiofibroma with intracellular accumulation of SPARC - a hypothesis (SPARC in nasopharyngeal angiofibroma).
  • Nasopharyngeal angiofibroma is a histologically benign tumor composed of stroma and vessels.
  • Some nasopharyngeal angiofibromas are resistant to surgical therapy because of extensive growth and occasionally bone destruction.
  • It has been shown that molecular factors supporting residual tissue after incomplete surgery might be targeted with pharmacotherapy as a cell based therapy.
  • Because the cell of origin of nasopharyngeal angiofibroma is not recognized yet, it would be of interest to discuss molecule(s) relevant to all the cell components of the growth.
  • Such molecule(s) may also regulate bone homing of the tumor.
  • We propose that in nasopharyngeal angiofibroma the molecule responding to the cues mentioned above is SPARC (secreted protein acidic rich in cystein).
  • We discuss SPARC-enabling formation of molecular complexes important for the angiogenic events and present nasopharyngeal angiofibroma as a hyperplastic angiogenic machinery or a "soil" without "seed".
  • Therapeutic targeting of SPARC in nasopharyngeal angiofibroma would be targeting of a molecule at the roots of cooperation between stromatogenesis and angiogenesis, coexpressed with Ki67 in the vascular compartment.
  • Considering the intracellular accumulation of SPARC, the benefit of (anti) SPARC therapy in nasopharyngeal angiofibroma is yet to be proved.
  • [MeSH-major] Angiofibroma / pathology. Nasopharyngeal Neoplasms / pathology. Osteonectin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681430.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Osteonectin
  •  go-up   go-down


9. Windfuhr JP, Remmert S: [Extranasopharyngeal angiofibroma of the nasal cavity and paranasal sinuses]. Laryngorhinootologie; 2004 May;83(5):308-16
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extranasopharyngeal angiofibroma of the nasal cavity and paranasal sinuses].
  • [Transliterated title] Extranasopharyngeale Angiofibrome der Nasenhaupt- und -nebenhöhlen.
  • BACKGROUND: Angiofibromas commonly arise in the nasopharynx in young male patients.
  • This study was undertaken to evaluate the incidence, clinical features and complications that may occur during the process of diagnosis and surgical therapy of angiofibromas outside the nasopharynx.
  • METHODS AND PATIENTS: Case report of a 13-year-old female patient and review of the literature.
  • RESULTS: Our patient received multi-agent chemotherapy elsewhere due to a misdiagnosed angiofibroma.
  • Computed Tomography (CT) revealed a maxillary tumor which was repeatedly biopsied.
  • The data of 42 patients were analyzed including our own case.
  • 32 patients were male, 10 female.
  • In 38 patients, symptoms developed within 12 months or less (average: 8.5 months).
  • Brisk bleeding occurred in 10 patients during tumor removal and resulted from biopsies in 11 of 20 patients.
  • Angiography detected hypervascularity in 3 of 4 patients.
  • There was no case with lethal outcome.
  • CONCLUSION: Extranasopharyngeal angiofibromas of the nasal cavity or paranasal sinuses should be included in the differential diagnosis of nasal tumors.
  • Compared to nasopharyngeal angiofibromas, more female patients are involved, symptoms develop more quickly but hypervascularity is less common.
  • Signs of questionable hypervascularity in Computed Tomography and Magnetic Resonance Imaging (MRI) should indicate arteriography prior to surgical procedures.
  • Preoperative embolization of hypervascular lesions during arteriography will reduce the risk of brisk bleeding during biopsy or surgical tumor removal.
  • [MeSH-major] Angiofibroma / diagnosis. Nose Neoplasms / diagnosis. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Angiography. Biopsy. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Infant, Newborn. Male. Maxillary Sinus Neoplasms / diagnosis. Maxillary Sinus Neoplasms / pathology. Maxillary Sinus Neoplasms / surgery. Middle Aged. Nasal Cavity / pathology. Nasal Cavity / surgery. Paranasal Sinuses / pathology. Paranasal Sinuses / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15143448.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 89
  •  go-up   go-down


10. Micozkadioglu H, Koc Z, Ozelsancak R, Yildiz I: Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient. Ren Fail; 2010;32(10):1233-6
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient.
  • Tuberous sclerosis complex (TSC) is an inherited multisystem disorder; it may involve kidney, brain, skin, lungs, and liver.
  • We report a 37-year-old female TSC patient presenting with skin lesions (angiofibromas, molluscum pendulum).
  • Treatment with rapamycin disclosed improvement in skin lesions.
  • The number and volume of angiofibromas and molluscum pendulum reduced progressively in 6 months.
  • During the ninth month of treatment, magnetic resonance imaging was repeated for renal and brain lesions.
  • Imaging results showed reduction in tumor and angiomyolipoma volumes.
  • Oral rapamycin therapy can improve renal, brain, and skin lesions in TSC disease.
  • Therefore, it may be an alternative therapy for TSC patients.
  • [MeSH-major] Brain Neoplasms / drug therapy. Immunosuppressive Agents / therapeutic use. Kidney Neoplasms / drug therapy. Sirolimus / therapeutic use. Skin Neoplasms / drug therapy. Tuberous Sclerosis / complications
  • [MeSH-minor] Adult. Angiofibroma / drug therapy. Angiofibroma / etiology. Facial Neoplasms / drug therapy. Female. Humans. Magnetic Resonance Imaging


11. Peces R, Peces C, Cuesta-López E, Pérez-Dueñas V, Vega-Cabrera C, Azorín S, Selgas R: Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex. Nephrol Dial Transplant; 2010 Nov;25(11):3787-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis complex (TSC) is caused by constitutively activated mammalian target of rapamycin (mTOR) resulting in non-malignant tumours of several organs including renal angiomyolipomas (AMLs).
  • AMLs may originate renal failure, hypertension and spontaneous life-threatening bleeding.
  • A 40-year-old man with sporadic TSC and a history of spontaneous bleeding from his left kidney AMLs received low-dose rapamycin for 12 months, and this was associated with a reduction in bilateral kidney AML volume, stabilization and even improvement of renal function.
  • There was also a reduction of facial angiofibromas, improvement of blood pressure control and absence of AML bleeding over this time period.
  • Brain lesion images remained stable, and no significant rapamycin-associated side effects were noted.
  • To the best of our knowledge, this is the first report of a case of reduction in renal AML volume together with preservation of renal function in a patient with TSC receiving low-dose rapamycin.
  • [MeSH-major] Angiomyolipoma / drug therapy. Kidney Neoplasms / drug therapy. Sirolimus / therapeutic use. TOR Serine-Threonine Kinases / antagonists & inhibitors. Tuberous Sclerosis / drug therapy
  • [MeSH-minor] Adult. Humans. Kidney / pathology. Kidney / physiopathology. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20663789.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


12. Haemel AK, O'Brian AL, Teng JM: Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol; 2010 Jul;146(7):715-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.
  • [MeSH-major] Angiofibroma / drug therapy. Facial Neoplasms / drug therapy. Immunosuppressive Agents / administration & dosage. Sirolimus / administration & dosage. Tuberous Sclerosis / complications

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JAMA Dermatol. 2013 Feb;149(2):203 [23426474.001]
  • [CommentIn] Arch Dermatol. 2011 Sep;147(9):1116-7 [21931059.001]
  • (PMID = 20644030.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


13. Türkmen M, Ertam I, Unal I, Dereli T: Facial angiofibromas of tuberous sclerosis: successful treatment with podophyllin. J Eur Acad Dermatol Venereol; 2009 Jun;23(6):713-4
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Facial angiofibromas of tuberous sclerosis: successful treatment with podophyllin.
  • [MeSH-major] Angiofibroma / drug therapy. Face. Podophyllin / therapeutic use. Tuberous Sclerosis / complications

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18785889.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 9000-55-9 / Podophyllin
  •  go-up   go-down






Advertisement